Recently approved and emerging drug options for migraine prophylaxis

References

• GBD. 2019. Diseases and injuries collaborators. global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020 Oct 17 396 10258 1204–1222. PMID: 33069326; PMCID: PMC7567026
   Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Jensen R, et al. Lifting the burden: the global campaign against headache. migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020 Dec 2;21(1):137. PMID: 33267788; PMCID: PMC7708887
   PubMedGoogle Scholar
• Luciani M, Negro A, Spuntarelli V, et al. Evaluating and managing severe headache in the emergency department. Epub 2021 Jan 4. PMID: 33297780. Expert Rev Neurother. 2021 Mar;21(3):277–285.
   PubMed Web of Science ®Google Scholar
• Bentivegna E, Luciani M, Paragliola V, et al. Recent advancements in tension-type headache: a narrative review. Epub 2021 Jul 2. PMID: 34128449. Expert Rev Neurother. 2021 Jul;21(7):793–803.
   PubMedGoogle Scholar
• Smitherman TA, Burch R, Sheikh H, et al. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Epub 2013 Mar 7. PMID: 23470015. Headache. 2013 Mar;53(3):427–436.
   PubMed Web of Science ®Google Scholar
• International Headache Society. International Classification of Headache Disorders (ICHD) −3. (2018). http://www.ichd-3.org/1-migraine/1-3-chronic-migraine/. Accessed 2021 Oct 30
   Google Scholar
• Ashina S, Bentivegna E, Martelletti P, et al. Structural and functional brain changes in migraine. Epub 2021 Feb 16. PMID: 33594593; PMCID: PMC8119592. Pain Ther. 2021 Jun;10(1):211–223.
   PubMed Web of Science ®Google Scholar
• Skorobogatykh K, van Hoogstraten Ws, Degan D, et al. European Headache Federation School of Advanced Studies (EHF-SAS). Functional connectivity studies in migraine: what have we learned? J Headache Pain. 2019 Nov 20;20(1):108. PMID: 31747874; PMCID: PMC6868768
   PubMedGoogle Scholar
• Patel S, Potter R, Matharu M, et al. CHESS team Development of an education and self-management intervention for chronic headache - CHESS trial (Chronic Headache Education and Self-management Study). J Headache Pain. 2019 Mar 18 20;1:28. PMID: 30885120; PMCID: PMC6734363
   PubMedGoogle Scholar
• Gaul C, Diener HC, Danesch U, et al. Study Group Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial J Headache Pain 2015 161 516
   PubMedGoogle Scholar
• Deen M, Correnti E, Kamm K, et al. European Headache Federation School of Advanced Studies (EHF-SAS). blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017 Sep 25;181:96. PMID: 28948500; PMCID: PMC5612904
   PubMedGoogle Scholar
• Do TP, Al-Saoudi A, Ashina M.Future prophylactic treatments in migraine: beyond anti-CGRP monoclonal antibodies and gepants.Rev Neurol (Paris).2021Sep;177(7)827–833. Epub 2021 Jul 20. PMID: 34294458
   PubMedGoogle Scholar
• Schou WS, Ashina S, Amin FM, et al. Calcitonin gene-related peptide and pain: a systematic review. Epub 2017 Mar 16. PMID: 28303458; PMCID: PMC5355411. J Headache Pain. 2017 Dec;18(1):34.
   PubMedGoogle Scholar
• Benemei S, Cortese F, Labastida-Ramírez A, et al. School of Advanced Studies of the European Headache Federation (EHF-SAS). Triptans and CGRP blockade - impact on the cranial vasculature. J Headache Pain. 2017 Oct 10;18(1):103. PMID: 29019093; PMCID: PMC5635141
   PubMedGoogle Scholar
• Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci. 1993;13(3):1167–1177.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. Drugs. 2005;65(18):2557–2567.
   PubMedGoogle Scholar
• Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs. 2014 May;28(5):389–399.
   PubMed Web of Science ®Google Scholar
• Favoni V, Giani L, Al-Hassany L, et al. European Headache Federation School of Advanced Studies (EHF-SAS). CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? J Headache Pain. 2019 Mar 12;20(1):27. PMID: 30866804; PMCID: PMC6734543.
   PubMedGoogle Scholar
• Pellesi L, Guerzoni S, Pini LA. Spotlight on anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date. Clin Pharmacol Drug Dev. 2017 Nov-Dec;6(6):534–547.
   PubMed Web of Science ®Google Scholar
• Yemisci M, Eikermann-Haerter K. Aura and stroke: relationship and what we have learnt from preclinical models. J Headache Pain. 2019 May 29;20(1):63. PMID: 31142262; PMCID: PMC6734247
   PubMedGoogle Scholar
• Kursun O, Yemisci M, van den Maagdenberg Amjm, et al. Migraine and neuroinflammation: the inflammasome perspective. J Headache Pain. 2021 Jun 10;22(1):55. PMID: 34112082; PMCID: PMC8192049
   PubMedGoogle Scholar
• Baumann A. Early development of therapeutic biologics—pharmacokinetics. Curr Drug Metab. 2006 Jan;7(1):15–21.
   PubMed Web of Science ®Google Scholar
• de Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. 2020 Jul;211:107528. Epub 2020 Mar 12. PMID: 32173558.Zhou H, Mascelli MA. Mechanisms of monoclonal antibody‐drug interactions. Annu Rev Pharmacol Toxicol. 2011;51:359–372.
   PubMed Web of Science ®Google Scholar
• Ho TW, Ho AP, Ge YJ, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. Cephalalgia. 2016;36(2):148–161.
   PubMed Web of Science ®Google Scholar
• Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet. 2019 Nov 9;394(10210):1765–1774.
   PubMed Web of Science ®Google Scholar
• Haanes KA, Edvinsson L, Sams A. Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies. J Headache Pain. 2020;21(1):26.
   PubMed Web of Science ®Google Scholar
• Nilsson C, Hansen TK, Rosenquist C, et al. Long-acting analogue of the calcitonin gene-related peptide induces positive metabolic effects and secretion of the glucagon-like peptide-1. Eur J Pharmacol. 2016 Feb 15; 773:24–31
   PubMedGoogle Scholar
• Sanford D, Luong L, Gabalski A, et al. An intraperitoneal treatment with Calcitonin Gene-Related Peptide (CGRP) Regulates Appetite, Energy Intake/Expenditure, and Metabolism. J Mol Neurosci. 2019 Jan;67(1):28–37.
   PubMedGoogle Scholar
• Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Erenumab – product information: summary of product characteristics
   Google Scholar
• Russo A, Silvestro M, Scotto Di Clemente F, et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain. 2020 Jun 9;21(1):69. PMID: 32517693; PMCID: PMC7282180
   PubMedGoogle Scholar
• Schwedt T, Reuter U, Tepper S, et al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain. 2018 Oct 1;19(1):92. PMID: 30276500; PMCID: PMC6755616
   PubMedGoogle Scholar
• Pavlovic JM, Paemeleire K, Göbel H, et al. Efficacy, and safety of erenumab in women with a history of menstrual migraine. J Headache Pain. 2020 Aug 3;21(1):95. PMID: 32746775; PMCID: PMC7398400
   PubMedGoogle Scholar
• Dodick DW, Ashina M, Brandes JL, et al. ARISE: a Phase 3 randomized trial of erenumab for episodic migraine. Epub 2018 Feb 22. PMID: 29471679. Cephalalgia. 2018 May;38(6):1026–1037.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Hallström Y, et al. One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study. Neurology. 2020 Aug 4;95(5):e469–e479. Epub 2020 Jul 7. PMID: 32636324; PMCID: PMC7455346
   PubMedGoogle Scholar
• Tepper S, Ashina M, Reuter U, et al.Safety, and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.Lancet Neurol.2017Jun;16(6)425–434. Epub 2017 Apr 28. PMID: 28460892
   PubMed Web of Science ®Google Scholar
• Spuntarelli V, Negro A, Luciani M, et al. Eptinezumab for the treatment of migraine. Epub 2021 Jun 1. PMID: 34009094. Expert Opin Biol Ther. 2021 Aug;21(8):999–1011.
   PubMed Web of Science ®Google Scholar
• Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241–254.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13(11):1100–1107.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13(11):1100–1107.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94(13):e1365–e1377.
   PubMed Web of Science ®Google Scholar
• Smith TR, Spierings ELH, Cady R, et al. Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies. J Headache Pain. 2021 Nov 25;22(1):143. PMID: 34823467
   PubMedGoogle Scholar
• Bigal ME, Walter S, Rapoport AM. Fremanezumab as a preventive treatment for episodic and chronic migraine. Epub 2019 May 22. PMID: 31043094. Expert Rev Neurother. 2019 Aug;19(8):719–728.
   PubMed Web of Science ®Google Scholar
• [cited 2021 Oct 30]. Available from: https://www.ema.europa.eu/en/documents/product-information/ajovy-epar-product-information_it.pdf
   Google Scholar
• Silberstein SD, Cohen JM, Yeung PP. Fremanezumab for the preventive treatment of migraine. Epub 2019 Jul 1. PMID: 31177856. Expert Opin Biol Ther. 2019 Aug;19(8):763–771.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018 May 15;319(19):1999–2008. PMID: 29800211; PMCID: PMC6583237.
   PubMedGoogle Scholar
• Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017 Nov 30;377(22):2113–2122. PMID: 29171818.
   PubMedGoogle Scholar
• Goadsby PJ, Silberstein SD, Yeung PP, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology. 2020 Nov 3;95(18):e2487–e2499. Epub 2020 Sep 10. PMID: 32913018; PMCID: PMC7682830.
   PubMedGoogle Scholar
• Lionetto L, Cipolla F, Guglielmetti M, et al. Fremanezumab for the prevention of chronic and episodic migraine. PMID: 31050694. Drugs Today (Barc). 2019 Apr;55(4):265–276.
   PubMed Web of Science ®Google Scholar
• Gklinos P, Mitsikostas DD. Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Neurol Disord. 2020 Apr 28;13:1756286420918088. PMID: 32426040; PMCID: PMC7222235.
   Google Scholar
• Schwedt TJ, Kuruppu DK, Dong Y, et al. Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. J Headache Pain. 2021 Mar 25;22(1):15. PMID: 33765912; PMCID: PMC7992932.
   PubMedGoogle Scholar
• Drugs and Lactation Database (LactMed). [Internet]. Bethesda (MD): National Library of Medicine (US); 2006. pp. 129-130. Galcanezumab. 2020 Jul 20. PMID: 30372007
   Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al.Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial.JAMA Neurol.2018Sep1;75:1080–1088. PMID: 29813147; PMCID: PMC61431199
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Epub 2018 May 31. PMID: 29848108. Cephalalgia. 2018 Jul;38(8):1442–1454.
   PubMed Web of Science ®Google Scholar
• Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo controlled REGAIN study. Neurology. 2018 Dec 11;91(24):e2211–e2221. Epub 2018 Nov 16. PMID: 30446596; PMCID: PMC6329331
   PubMedGoogle Scholar
• Ailani J, Andrews JS, Rettiganti M, et al. Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials). J Headache Pain. 2020 Oct 17;21(1):123. PMID: 33069214; PMCID: PMC7568830.
   PubMedGoogle Scholar
• Raffaelli B, Mussetto V, Israel H, et al. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J Headache Pain. 2019 Jun 3;20(1):66. PMID: 31159727; PMCID: PMC6734267
   PubMedGoogle Scholar
• Becker WJ. Botulinum toxin in the treatment of headache. Toxins (Basel). 2020 Dec 17;12(12):803. PMID: 33348571; PMCID: PMC7766412
   Google Scholar
• Tassorelli C, Tedeschi G, Sarchielli P, et al. Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Epub 2017 Dec 27. PMID: 29280408. Expert Rev Neurother. 2018 Feb;18(2):167–176.
   PubMed Web of Science ®Google Scholar
• Sacco S, Russo A, Geppetti P, et al. What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. Epub 2020 Sep 30. PMID: 32990477. Expert Rev Neurother. 2020 Dec;20(12):1275–1286.
   PubMed Web of Science ®Google Scholar
• Burstein R, Blumenfeld AM, Silberstein SD, et al.Mechanism of action of onabotulinumtoxina in chronic migraine: a narrative review.Headache.2020Jul;60(7)1259–1272. Epub 2020 Jun 30. PMID: 32602955; PMCID: PMC7496564
   PubMed Web of Science ®Google Scholar
• Schueler M, Neuhuber WL, De Col R, et al. Innervation of rat and human dura mater and pericranial tissues in the parieto-temporal region by meningeal afferents. Epub 2014 May 6. PMID: 24673461. Headache. 2014 Jun;54(6):996–1009.
   PubMedGoogle Scholar
• Cernuda-Morollón E, Ramón C, Martínez-Camblor P, et al. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. PMID: 25735000. Pain. 2015 May;156(5):820–824.
   PubMed Web of Science ®Google Scholar
• Matharu M, Halker R, Pozo-Rosich P, et al. The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis. Epub 2017 Aug 1. PMID: 28766236; PMCID: PMC5539058. J Headache Pain. 2017 Dec;18(1):78.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollón E, Ramón C, Larrosa D, et al. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after one year? Epub 2014 Nov 27. PMID: 25431141. Cephalalgia. 2015 Sep;35(10):864–868.
   PubMed Web of Science ®Google Scholar
• Bendtsen L, Sacco S, Ashina M, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. J Headache Pain. 2018 Sep 26;19(1):91. PMID: 30259200; PMCID: PMC6755553
   PubMedGoogle Scholar
• Sandrini G, Perrotta A, Tassorelli C, et al. Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. Epub 2011 Apr 16. PMID: 21499747; PMCID: PMC3139089. J Headache Pain. 2011 Aug;12(4):427–433.
   PubMedGoogle Scholar
• Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. PMID: 19912346. Headache. 2009 Nov-Dec;49(10):1466–1478.
   PubMed Web of Science ®Google Scholar
• D’Antona L, Matharu M. Identifying and managing refractory migraine: barriers and opportunities? J Headache Pain. 2019 Aug 23;20(1):89. PMID: 31443629; PMCID: PMC6734232
   PubMed Web of Science ®Google Scholar
• Pellesi L, Do TP, Ashina H, et al. Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale? Epub 2020 May 21. PMID: 32437038. Headache. 2020 Jun;60(6):1056–1065.
   PubMed Web of Science ®Google Scholar
• Eftekhari S, Warfvinge K, Blixt FW, et al. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. Epub 2013 Aug 17. PMID: 23958278. J Pain. 2013 Nov;14(11):1289–1303.
   PubMed Web of Science ®Google Scholar
• American Headache Society. The American Headache Society Position Statement on Integrating New Migraine Treatments into Clinical Practice.The American headache society position statement on integrating new migraine treatments into clinical practice. Headache. 2019. Jan;;59. 1:1–18.Epub 2018 Dec 10 PMID: 30536394
   Google Scholar
• Sacco S, Braschinsky M, Ducros A, et al. European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020 Jun 16;21(1):76. PMID: 32546227; PMCID: PMC7296705.
   PubMedGoogle Scholar
• Toni T, Tamanaha R, Newman B, et al. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series. Neurol Sci. 2021 Aug 18;42(12):5373–5376. Epub ahead of print. PMID: 34409517
   PubMedGoogle Scholar
• Talbot J, Stuckey R, Crawford L, et al. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes. J Headache Pain. 2021 Jan 9;22(1):5. PMID: 33421995; PMCID: PMC7797151
   PubMedGoogle Scholar
• Tepper DG. Gepants. Headache. 2020May;60(5):1037–1039. PMID: 32337726.
   PubMed Web of Science ®Google Scholar
• Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019. Apr17;20:1:37. PMID: 30995909; PMCID: PMC6734360
   PubMedGoogle Scholar
• Moreno-Ajona D, Pérez-Rodríguez A, Goadsby PJ. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? PMID: 32251023. Curr Opin Neurol. 2020 Jun;33(3):309–315.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Dodick DW, Ailani J, et al.Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial.JAMA.2019Nov19;322:1887–1898. PMID: 31742631;PMCID: PMC686532319
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the Treatment of Migraine. N Engl J Med. 2019 Dec 5;381(23):2230–2241. PMID: 31800988
   PubMedGoogle Scholar
• Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019 Jul 11;381(2):142–149. PMID: 31291516
   PubMed Web of Science ®Google Scholar
• Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Epub 2013 Aug 21. PMID: 23965396. Cephalalgia. 2014 Feb;34(2):114–125.
   PubMed Web of Science ®Google Scholar
• Negro A, Martelletti P. Rimegepant for the treatment of migraine. PMID: 33332483. Drugs Today (Barc). 2020 Dec;56(12):769–780.
   PubMed Web of Science ®Google Scholar
• Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021 Jan 2;397(10268):51–60. Epub 2020 Dec 15. PMID: 33338437
   PubMedGoogle Scholar
• Ailani J, Lipton RB, Goadsby PJ, et al.; ADVANCE Study Group. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021 Aug 19;385(8):695–706. PMID: 34407343.
   PubMedGoogle Scholar
• Daniel O, Mauskop A.Nutraceuticals in acute and prophylactic treatment of migraine.Curr Treat Options Neurol.2016Apr;18(4)14. PMID: 26923604
   PubMed Web of Science ®Google Scholar
• Pfaffenrath V, Diener HC, Fischer M, et al.,Investigators.The efficacy and safety of tanacetum parthenium (feverfew) in migraine prophylaxis–a double-blind, multicentre, randomized placebo-controlled dose-response study.Cephalalgia.2002Sep; 22(7):523–532. x. PMID: 12230594
   PubMed Web of Science ®Google Scholar
• Bianchi A, Salomone S, Caraci F, et al. Role of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis. Vitam Horm. 2004;69:297–312. PMID: 15196887.
   PubMedGoogle Scholar
• Sparaco M, Feleppa M, Lipton RB, et al. Mitochondrial dysfunction and migraine: evidence and hypotheses. x. PMID: 16556237. Cephalalgia. 2006 Apr;26(4):361–372.
   PubMedGoogle Scholar
• Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. PMID: 9484373. Neurology. 1998 Feb;50(2):466–470.
   PubMed Web of Science ®Google Scholar
• Sándor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005 Feb 22;64(4):713–715. PMID: 15728298
   PubMedGoogle Scholar
• Khani S, Hejazi SA, Yaghoubi M, et al. Comparative study of magnesium, sodium valproate, and concurrent magnesium-sodium valproate therapy in the prevention of migraine headaches: a randomized controlled double-blind trial. J Headache Pain. 2021 Apr 7;22(1):21. PMID: 33827421; PMCID: PMC8028183
   PubMedGoogle Scholar
• Teigen L, Boes CJ. An evidence-based review of oral magnesium supplementation in the preventive treatment of migraine. Epub 2014 Dec 22. PMID: 25533715. Cephalalgia. 2015 Sep;35(10):912–922.
   PubMed Web of Science ®Google Scholar
• Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. x. PMID: 8792038. Cephalalgia. 1996 Jun;16(4):257–263.
   PubMed Web of Science ®Google Scholar
• Clemow DB, Johnson KW, Hochstetler HM, et al. Lasmiditan mechanism of action - review of a selective 5-HT1F agonist. J Headache Pain. 2020 Jun 10;21(1):71. PMID: 32522164; PMCID: PMC7288483
   PubMedGoogle Scholar
• Lamb YN. Lasmiditan: first approval. Drugs. 2019;79(18):1989–1996. DOI: https://doi.org/10.1007/s40265-019-01225-7.
   PubMed Web of Science ®Google Scholar
• Yang C-P, Liang C-S, Chang C-M, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Network Open. 2021 Oct 1;4(10):e2128544. PMID: 34633423; PMCID: PMC8506232
   PubMedGoogle Scholar
• Pharmacokinetics S-FD. Pharmacodynamics and drug-drug interactions of new anti-migraine drugs-lasmiditan, gepants, and Calcitonin-Gene-Related Peptide (CGRP) receptor monoclonal antibodies. Pharmaceutics. 2020 Dec 3;12(12):1180. PMID: 33287305; PMCID: PMC7761673
   Google Scholar
• 62nd annual scientific meeting American headache society1. Headache. 2020;60(Suppl 1): 1–156. DOI:https://doi.org/10.1111/head.13854.
   PubMedGoogle Scholar
• Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021 Apr 17;397(10283):1505–1518. Epub 2021 Mar 25. PMID: 33773612
   PubMedGoogle Scholar
• Ghanizada H, Al-Karagholi MA, Arngrim N, et al. PACAP27 induces migraine-like attacks in migraine patients. Epub 2019 Jul 12. PMID: 31299857. Cephalalgia. 2020 Jan;40(1):57–67.
   PubMedGoogle Scholar
• Safety, Tolerability and pharmacokinetics of ALD1910 in healthy men and woman. https://clinicaltrials.gov/ct2/show/NCT04197349https://clinicaltrials.gov/ct2/show/NCT04498910https://clinicaltrials.gov/ct2/show/NCT04197349https://clinicaltrials.gov/ct2/show/NCT04498910. A Study of LY3451838 in Participants with Migraine. [cited 2021 Oct 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT04197349https://clinicaltrials.gov/ct2/show/NCT04498910https://clinicaltrials.gov/ct2/show/NCT04197349https://clinicaltrials.gov/ct2/show/NCT04498910.
   Google Scholar
• Cernuda-Morollón E, Martínez-Camblor P, Ramón C, et al. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine. Headache. 2014 Jun;54(6):987–995. Epub 2014 May 6. PMID: 24673487.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollón E, Martínez-Camblor P, Alvarez R, et al. Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine. Cephalalgia. 2015 Apr;35(4):310–316. Epub 2014 May 20. PMID: 24847167.
   PubMed Web of Science ®Google Scholar
• Hanci F, Kilinc YB, Kilinc E, et al. Plasma levels of vasoactive neuropeptides in pediatric patients with migraine during attack and attack-free periods. Cephalalgia. 2021 Feb;41(2):166–175. Epub 2020 Sep 9. PMID: 32903061.
   PubMed Web of Science ®Google Scholar
• Tuka B, Helyes Z, Markovics A, et al. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Epub 2013 Apr 18. PMID: 23598374. Cephalalgia. 2013 Oct;33(13):1085–1095.
   PubMed Web of Science ®Google Scholar
• Zagami AS, Edvinsson L, Goadsby PJ. Pituitary adenylate cyclase activating polypeptide and migraine. Epub 2014 Nov 12. PMID: 25574477; PMCID: PMC4284128. Ann Clin Transl Neurol. 2014 Dec;1(12):1036–1040.
   PubMed Web of Science ®Google Scholar
• Schytz HW, Birk S, Wienecke T, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Epub 2008 Dec 3. PMID: 19052139. Brain. 2009 Jan;132(Pt 1):16–25.
   PubMedGoogle Scholar
• Ashina M, Doležil D, Bonner JH, et al. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylates cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Epub 2020 Nov 24. PMID: 33231489; PMCID: PMC7786389. Cephalalgia. 2021 Jan;41(1):33–44.
   PubMed Web of Science ®Google Scholar
• Kooshki R, Abbasnejad M, Esmaeili-Mahani S, et al. Activation orexin 1 receptors in the ventrolateral periaqueductal gray matter attenuate nitroglycerin-induced migraine attacks and calcitonin gene related peptide up-regulation in trigeminal nucleus caudalis of rats. Neuropharmacology. 2020 Nov 1;178:107981. Epub 2020 Jul 31. PMID: 32745488.
   PubMedGoogle Scholar
• Hoffmann J, Supronsinchai W, Akerman S, et al. Evidence for orexinergic mechanisms in migraine. Neurobiol Dis. 2015 Feb;74:137–143. Epub 2014 Nov 4. PMID: 25447225.
   PubMed Web of Science ®Google Scholar
• Chabi A, Zhang Y, Jackson S, et al. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Epub 2014 Aug 8. PMID: 25106663. Cephalalgia. 2015 Apr;35(5):379–388.
   PubMed Web of Science ®Google Scholar
• Zielman R, Wijnen JP, Webb A, et al. Cortical glutamate in migraine. Brain. 2017 Jul 1;140(7):1859–1871. PMID: 28633367
   PubMedGoogle Scholar
• Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55(1):533–552. Epub 2014 Oct 8. PMID: 25340934; PMCID: PMC4392770.
   PubMed Web of Science ®Google Scholar
• Noruzzadeh R, Modabbernia A, Aghamollaii V, et al. Memantine for prophylactic treatment of migraine without aura: a randomized double-blind placebo-controlled study. Epub 2015 Dec 6. PMID: 26638119. Headache. 2016 Jan;56(1):95–103.
   PubMed Web of Science ®Google Scholar
• Shanmugam S, Karunaikadal K, Varadarajan S, et al. Memantine ameliorates migraine headache. PMID: 31359939; PMCID: PMC6613428. Ann Indian Acad Neurol. 2019 Jul-Sep;22(3):286–290.
   PubMedGoogle Scholar
• Kayama Y, Shibata M, Takizawa T, et al. Functional interactions between transient receptor potential M8 and transient receptor potential V1 in the trigeminal system: relevance to migraine pathophysiology. Epub 2017 May 29. PMID: 28554243; PMCID: PMC5896691. Cephalalgia. 2018 Apr;38(5):833–845.
   PubMedGoogle Scholar
• Chasman DI, Schürks M, Anttila V, et al. Genome-wide association study reveals three susceptibility loci for common migraine in the general population. Nat Genet. 2011 Jun 12;43(7):695–698. PMID: 21666692; PMCID: PMC3125402
   PubMedGoogle Scholar
• Phase I, and Double-Blind P, MAD study to evaluate the safety, tolerability, PK, and PD of AMG 333 in healthy subjects and migraine subjects. https://clinicaltrials.gov/ct2/show/NCT02132429https://clinicaltrials.gov/ct2/show/NCT04183283. A Study of LY3526318 in Healthy Women. [cited 2021 Oct 30]. Available from: https://clinicaltrials.gov/ct2/show/NCT02132429https://clinicaltrials.gov/ct2/show/NCT04183283.
   Google Scholar
• Lipton RB, Bigal ME, Diamond M, et al. AMPP Advisory Group Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 Jan 30 68;5:343–349. PMID: 17261680
   PubMedGoogle Scholar
• Ashina M, Katsarava Z, Do TP, et al. Migraine: epidemiology and systems of care. Lancet. 2021 Apr 17;397(10283):1485–1495. Epub 2021 Mar 25. PMID: 33773613
   PubMedGoogle Scholar
• Vécsei L, Lukács M, Tajti J, et al. The therapeutic impact of new migraine discoveries. Curr Med Chem. 2019;26(34):6261–6281. PMID: 29848264.
   PubMedGoogle Scholar
• Lindblad M, Hougaard A, Amin FM, et al. Can migraine aura be provoked experimentally? A systematic review of potential methods for the provocation of migraine aura. Epub 2016 Sep 29. PMID: 26946372. Cephalalgia. 2017 Jan;37(1):74–88.
   PubMedGoogle Scholar
• Al-Karagholi MA, Gram C, Nielsen CAW, et al. Targeting BKCa channels in migraine: rationale and perspectives. PMID: 32060729. CNS Drugs. 2020 Apr;34(4):325–335.
   PubMedGoogle Scholar
• Kokoti L, Al-Karagholi MA, Ashina M. Latest insights into the pathophysiology of migraine: the ATP-sensitive potassium channels. Curr Pain Headache Rep. 2020 Dec 3;24(12):77. PMID: 33270149
   PubMedGoogle Scholar
• Martelletti P, Luciani M, Spuntarelli V, et al. Deprescribing in migraine. Epub 2021 Mar 25. PMID: 33749470. Expert Opin Drug Saf. 2021 Jun;20(6):623–625.
   PubMed Web of Science ®Google Scholar